2 stocks that could be slammed by Donald Trump

Donald Trump’s policies are looking like very bad news for these two UK companies.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Donald Trump has undoubtedly been a net positive for equities in the US. The new president’s talk of lower taxes, lower regulation and an economic stimulus programme breathed new life into the shares of banks, energy producers and builders alike. But on this side of the Atlantic I have my fears that Trump’s bombastic attacks on certain industries leaves several UK stocks in danger of being hugely negatively affected by his potential policies.

First up is speciality drug producer Shire (LSE: SHP). What worries me about Trump and Shire is that the he’s been quoted in the press as saying things such as “the pricing has been astronomical” and “you folks [drug companies] have done a very great job over the years but we have to get the prices down.

And Trump could definitely do something about bringing down drug prices either through direct legislation or giving government-run medical programmes the ability to negotiate their prices with drug makers. This is a common sense move that has somehow escaped Congress’s attention thus far.

This is a problem for all drug makers but is an extra worry for Shire as the company’s business model is based on developing drugs for rare diseases and then charging very, very high prices for the treatment.

Aside from concerns that its products may fetch lower prices, I’m also worried because Shire has taken on a whopping $23bn in net debt to fund a series of huge acquisitions that have made it a world leader in rare disease treatments. If the company’s ambitious sales and profit targets are met this won’t be a major problem, but should Trump take an axe to pharmaceutical prices, it certainly would be.

Rough seas ahead for global trade?

Also at risk of becoming collateral damage to Trump’s policies is ship broker Clarkson (LSE: CKN). It has already seen profits drop in the past year as a slowdown in demand for oil & gas-related ships and an oversupply of cargo vessels have led to low prices for bulk shipping.

The threat from Trump to Clarkson is if the new president embarks on his much-talked-about plan to impose tariffs on trading partners such as Mexico or, more worryingly, China. Were Trump to slap import taxes on goods from China, the Chinese would undoubtedly retaliate, threatening to send the volume of trade between these important partners plummeting.

This would be a problem for Clarkson because its broking services account for more than 85% of underlying pre-tax profits and would be negatively impacted should volumes and the price of cargo shipping fall.

The upside is that as a broker, Clarkson doesn’t own any ships and is paid a commission per deal arranged, so is somewhat protected from any downturn. Indeed, the company has weathered problems in the offshore oil & gas industry with aplomb and remains solidly profitable and has a cash-heavy balance sheet.

But with shares of the company trading hands at a lofty 25 times forward earnings would-be investors would do well to image the potential threat from Trump’s policies before buying shares.

Are you looking for Trump-resistant shares?

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Ian Pierce has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Fireworks display in the shape of willow at Newcastle, Co. Down , Northern Ireland at Halloween.
Investing Articles

The Anglo American share price soars to £25, but I’m not selling!

On Thursday, the Anglo American share price soared after mega-miner BHP Group made an unsolicited bid for it. But I…

Read more »

Investing Articles

Now 70p, is £1 the next stop for the Vodafone share price?

The Vodafone share price is back to 70p, but it's a long way short of the 97p it hit in…

Read more »

Concept of two young professional men looking at a screen in a technological data centre
Investing Articles

If I’d put £5,000 in Nvidia stock at the start of 2024, here’s what I’d have now

Nvidia stock was a massive winner in 2023 as the AI chipmaker’s profits surged across the year. How has it…

Read more »

Light bulb with growing tree.
Investing Articles

3 top investment trusts that ‘green’ up my Stocks and Shares ISA

I’ll be buying more of these investment trusts for my Stocks and Shares ISA given the sustainable and stable returns…

Read more »

Investing Articles

8.6% or 7.2%? Does the Legal & General or Aviva dividend look better?

The Aviva dividend tempts our writer. But so does the payout from Legal & General. Here he explains why he'd…

Read more »

a couple embrace in front of their new home
Investing Articles

Are Persimmon shares a bargain hiding in plain sight?

Persimmon shares have struggled in 2024, so far. But today's trading update suggests sentiment in the housing market's already improving.

Read more »

Market Movers

Here’s why the Unilever share price is soaring after Q1 earnings

Stephen Wright isn’t surprised to see the Unilever share price rising as the company’s Q1 results show it’s executing on…

Read more »

Investing Articles

Barclays’ share price jumps 5% on Q1 news. Will it soon be too late to buy?

The Barclays share price has been having a great time this year, as a solid Q1 gives it another boost.…

Read more »